Acute Lymphoblastic Leukaemia Recurrent Recruiting Phase 2 Trials for Rituximab (DB00073)

Also known as: Acute, recurrent Lymphoblastic Leukaemia / Acute, recurrent Lymphoblastic Leukemia / Recurrent Acute lymphoblastic leukemia / Acute, relapsed Lymphoblastic Leukemia / Relapsed Acute Lymphoblastic Leukemia / Acute lymphoblastic leukemia recurrent / Relapsed ALL / Acute lymphocytic leukemia recurrent / Acute lymphocytic leukaemia recurrent

IndicationStatusPhase
DBCOND0083559 (Acute Lymphoblastic Leukaemia Recurrent)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02199184Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaTreatment
NCT03136146Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaTreatment
NCT03147612Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaTreatment